Karen J. Buchkovich
Cold Spring Harbor Laboratory
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Karen J. Buchkovich.
Cell | 1989
Karen J. Buchkovich; Linda A. Duffy; Ed Harlow
p105-RB is the product of the retinoblastoma tumor suppressor gene. It is a nuclear phosphoprotein hypothesized to act as an inhibitor of cellular proliferation, yet surprisingly it is present in actively dividing cells. To look for changes in p105-RB that may regulate its activity during the cell cycle, we generated synchronized cell populations and followed their progression through the cell cycle. p105-RB is synthesized throughout the cycle, but is phosphorylated in a phase-specific manner. In the G0 and G1 phases of the cell cycle, an unphosphorylated species of the protein is the only detectable form, whereas in the S and G2/M phases, multiple phosphorylated species of p105-RB are detected.
The EMBO Journal | 1991
Jacqueline A. Lees; Karen J. Buchkovich; D R Marshak; C W Anderson; Ed Harlow
The retinoblastoma gene product (pRB) is a nuclear phosphoprotein that is thought to play a key role in the negative regulation of cellular proliferation. pRB is phosphorylated in a cell cycle dependent manner, and studies in both actively dividing and differentiated cells suggest that this modification may be essential for cells to progress through the cell cycle. Using tryptic phosphopeptide mapping we have shown that pRB is phosphorylated on multiple serine and threonine residues in vivo and that many of these phosphorylation events can be mimicked in vitro using purified p34cdc2. Using synthetic peptides corresponding to potential cdc2 phosphorylation sites, we have developed a strategy which has allowed the identification of five sites. S249, T252, T373, S807 and S811 are phosphorylated in vivo, and in each case these sites correspond closely to the consensus sequence for phosphorylation by p34cdc2. This and the observation that pRB forms a specific complex with p34cdc2 in vivo suggests that p34cdc2 or a p34cdc2‐related protein is a major pRB kinase.
Cell | 1989
Nicholas J. Dyson; Karen J. Buchkovich; Peter Whyte; Ed Harlow
The association between the retinoblastoma protein (p105-RB) and either the large T antigen of SV40 or the E1A proteins of adenovirus is thought to be an important step in transformation by these viral oncogenes. E1A and large T antigen share a small region of amino acid homology that is necessary for high affinity binding with p105-RB. Mutations of this homology region were shown to reduce drastically the frequency of transformation mediated by the E1A or large T oncogenes. Previously, this small region in E1A was shown to be sufficient for interaction with a second cellular protein of 107,000 daltons (107K). Here we show that in human cells, the large T antigens of SV40 or JC virus also form complexes with 107K. Demonstration of complexes between 107K and the large T antigens of SV40 and JC virus suggests that these associations may represent another component of a common mechanism for transformation between adenoviruses and polyoma viruses.
Molecular and Cellular Biology | 1992
Qianjin Hu; J. A. Lees; Karen J. Buchkovich; Ed Harlow
The protein product (pRB) of the retinoblastoma susceptibility gene functions as a negative regulator of cell proliferation, and its activity appears to be modulated by phosphorylation. Using a new panel of anti-human pRB monoclonal antibodies, we have investigated the biochemical properties of this protein. These antibodies have allowed us to detect a pRB-associated kinase that has been identified as the cell cycle-regulating kinase p34cdc2 or a closely related enzyme. Since this associated kinase phosphorylates pRB at most of the sites used in vivo, these results suggest that this kinase is one of the major regulators of pRB. The associated kinase activity follows the pattern of phosphorylation seen for pRB in vivo. The associated kinase activity is not seen in the G1 phase but appears in the S phase, and the levels continue to increase throughout the remainder of the cell cycle.
Cold Spring Harbor Symposia on Quantitative Biology | 1988
Jonathan M. Horowitz; Stephen H. Friend; Robert A. Weinberg; Peter Whyte; Karen J. Buchkovich; Ed Harlow
Normal and neoplastic cell growth is controlled by a complex interacting network of genes and proteins. The number of separate components in this network and the lines of communication between them remain poorly defined. Over the past decade, oncogenes and proto-oncogenes have attracted a great share of the attention of those interested in the molecular biology of cell growth. These genes sit at critical points in this complex signaling network, but they represent only a portion of the key elements controlling cell growth. The oncogenes described to date function in a number of distinct ways (Bishop 1983; Varmus 1984; Weinberg 1985). They may encode cellular proteins in the cytoplasm and nucleus that exert a variety of effects on cell phenotype. These effects include changes in growth factor dependence, morphology, sugar uptake and metabolism, and ability to grow indefinitely in culture (immortalization).
Nature | 1988
Peter Whyte; Karen J. Buchkovich; Jonathan M. Horowitz; Stephen H. Friend; Margaret Raybuck; Robert A. Weinberg; Ed Harlow
Science | 1989
Jonathan M. Horowitz; David W. Yandell; Sang-Ho Park; S. Canning; Peter Whyte; Karen J. Buchkovich; Ed Harlow; Robert A. Weinberg; Thaddeus P. Dryja
Molecular Biology of the Cell | 1996
Karen J. Buchkovich; Carol W. Greider
Clinical Cancer Research | 2002
Sheila J. Miknyoczki; Weihua Wan; Hong Chang; Pawel Dobrzanski; Bruce Ruggeri; Craig A. Dionne; Karen J. Buchkovich
Archive | 2001
Karen J. Buchkovich; Craig A. Dionne; Sheila J. Miknyoczki; Bruce Ruggeri